Story perspectives

Lilly, Novo to launch oral GLP-1 drugs in India 2027

By Drooid · Oct 2, 2026, 1:59 PM UTC · How we work

Summary

Novo, Lilly Launch Oral

Novo Nordisk and Eli Lilly will launch oral GLP-1 drugs in India in early 2027.
Lilly’s orforglipron is expected around January-February 2027, followed by Novo’s oral Wegovy.
Oral pills achieve 12-15% weight loss versus 15-22% for injections.
The OCTANE study found 194 switchers lost 4.1% weight in three months.
Novo CEO Mike Doustdar said oral drugs could represent half the market by 2030.

Summary

Lilly Invests India

Eli Lilly commits $1 billion to Indian contract-manufacturing and technical hubs for several years.
Over 600 engineers work at Lilly’s Hyderabad centre on AI and software solutions.
Lilly will produce oral drug Foundayo with Indian partners to serve global markets via scalable synthesis.
Generic semaglutide in India sells for INR1,500-INR5,500 monthly, far below Mounjaro’s INR13,000-INR25,000 price.
Lilly’s strategy seeks to make India a top-five global market, expanding trials and access initiatives.

1 of 2

Novo, Lilly Launch Oral

Novo Nordisk and Eli Lilly will launch oral GLP-1 drugs in India in early 2027.
Lilly’s orforglipron is expected around January-February 2027, followed by Novo’s oral Wegovy.
Oral pills achieve 12-15% weight loss versus 15-22% for injections.
The OCTANE study found 194 switchers lost 4.1% weight in three months.
Novo CEO Mike Doustdar said oral drugs could represent half the market by 2030.

1 / 2